Vaxtex Cotfab

Why is Vaxtex Cotfab Ltd falling/rising?

As of 24-Jun, Vaxtex Cotfab Ltd's stock price is at 1.20, reflecting a decline of 0.83%. Despite recent positive financial results, the stock is underperforming significantly, facing bearish trends and concerns about its long-term fundamentals and debt servicing ability.

As of 24-Jun, Vaxtex Cotfab Ltd's stock price is falling, currently at 1.20, which reflects a change of -0.01 (-0.83%). The stock has underperformed its sector by 3.59% today and is trading below its moving averages across various time frames, indicating a bearish trend. Over the past week, the stock has declined by 8.40%, while the broader market, represented by the Sensex, has only decreased by 0.27%. <BR><BR>Despite positive financial results over the last five quarters, including a significant growth in net sales and a high return on capital employed, the stock's long-term fundamentals appear weak. The company is facing operating losses and has a poor EBIT to interest ratio of -1.24, which raises concerns about its ability to service debt. Additionally, while institutional investors have increased their stake, the overall performance of the stock has been lackluster, with a year-to-date decline of 41.46%, compared to a smaller drop of 8.07% in the broader market. <BR><BR>These factors contribute to the current downward pressure on Vaxtex Cotfab Ltd's stock price.

Which are the latest news on Vaxtex Cotfab?

What does Vaxtex Cotfab do?

Vaxtex Cotfab Ltd is a Micro Cap company in the Garments & Apparels industry, incorporated in 2005, with a recent net profit of 1 Cr for March 2026 and a market cap of INR 26 Cr. Key metrics include a P/E of 5.00, a debt-equity ratio of 0.18, and a return on equity of 24.63%.

Overview:<BR>Vaxtex Cotfab Ltd operates in the Garments & Apparels industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Vaxtex Cotfab Limited was incorporated in 2005 under the name "Foolproof Vyapaar Private Limited" in Kolkata, West Bengal. The company changed its name to "Vaxtex Cotfab Private Limited" in 2015. The most recent quarterly results reported net profit for March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>Market-cap value: INR 26 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 5.00<BR>Industry P/E: 23<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.18<BR>Return on Equity: 24.63%<BR>Price to Book: 1.15<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

How big is Vaxtex Cotfab?

As of 10th June, Vaxtex Cotfab Ltd has a market capitalization of 26.00 Cr, with recent net sales of 11.17 Cr and a net profit of 5.53 Cr. Shareholder's funds are 18.34 Cr and total assets amount to 48.29 Cr.

As of 10th June, Vaxtex Cotfab Ltd has a market capitalization of 26.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vaxtex Cotfab reported Net Sales of 11.17 Cr and a Net Profit of 5.53 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 18.34 Cr and Total Assets of 48.29 Cr.

Who are in the management team of Vaxtex Cotfab?

The management team of Vaxtex Cotfab includes Khushat Gupta and Mithleshkumar M Agrawal as Managing Directors, along with Mithleshkumar M Agrawal as a Director, and independent directors Dhavalbhai Pravinbhai Patel, Poonam Pravinbhai Panchal, and Pranav Manoj Vajani.

The management team of Vaxtex Cotfab includes the following individuals:<BR><BR>1. Khushat Gupta - Managing Director<BR>2. Mithleshkumar M Agrawal - Managing Director<BR>3. Mithleshkumar M Agrawal - Director<BR>4. Dhavalbhai Pravinbhai Patel - Independent Director<BR>5. Poonam Pravinbhai Panchal - Independent Director<BR>6. Pranav Manoj Vajani - Independent Director<BR><BR>If you need more information about their roles or the company, feel free to ask!

Who are the peers of the Vaxtex Cotfab?

Vaxtex Cotfab's peers include Super Spinning, Morarjee Text., Spenta Intl., Pasupati Spinng., Hindoo. Mills, Aditya Spinners, Davin Sons Reta, Katare Spinning, and Maris Spinners. Vaxtex Cotfab leads in 1-year returns at 51.65%, while most peers exhibit below-average management risk and growth, with Super Spinning showing the lowest return at -52.45%.

Peers: The peers of Vaxtex Cotfab are Super Spinning, Morarjee Text., Spenta Intl., Pasupati Spinng., Hindoo. Mills, Aditya Spinners, Davin Sons Reta, Katare Spinning, Maris Spinners.<BR><BR>Quality Snapshot: Excellent management risk is observed at Davin Sons Reta, while Average management risk is found at Morarjee Text. and Spenta Intl., and the rest have Below Average management risk. For Growth, Excellent growth is seen at Davin Sons Reta, Average growth at Morarjee Text. and the rest, while Below Average growth is noted for Super Spinning, Pasupati Spinng., Hindoo. Mills, Aditya Spinners, Katare Spinning, and Maris Spinners. In terms of Capital Structure, Davin Sons Reta has an Average rating, while the rest, including Super Spinning, Vaxtex Cotfab, Morarjee Text., Spenta Intl., Pasupati Spinng., Hindoo. Mills, Aditya Spinners, Katare Spinning, and Maris Spinners, have Below Average ratings.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Vaxtex Cotfab at 51.65%, while the peer with the lowest is Super Spinning at -52.45%, indicating that Vaxtex Cotfab significantly outperforms its peers in this regard. Additionally, Super Spinning, Vaxtex Cotfab, and Pasupati Spinng. have negative six-month returns.

Should I buy, sell or hold Vaxtex Cotfab Ltd?

Are Vaxtex Cotfab Ltd latest results good or bad?

Vaxtex Cotfab Ltd's latest results are concerning, showing zero net sales in Q4 FY26, an 80% drop in net profit largely from non-operational income, and a significant decline in promoter holdings, indicating severe operational challenges and a weak financial outlook. Investors should reassess their positions due to the company's deteriorating fundamentals.

The latest results for Vaxtex Cotfab Ltd are concerning and indicate significant operational challenges. In the fourth quarter of FY26, the company reported zero net sales, a drastic decline of 100% from the previous quarter, where it had generated ₹8.88 crores. This complete absence of revenue is alarming and suggests severe issues within the business model.<BR><BR>While the company did report a net profit of ₹0.79 crores, this was down 80% from the previous quarter and largely derived from non-operational income rather than core business activities. The operating profit before depreciation, interest, and tax was negative, highlighting the inability to generate positive cash flows from operations.<BR><BR>Additionally, promoter holdings have plummeted from 18.10% in March 2025 to just 0.50% by March 2026, signaling a lack of confidence from those most familiar with the company. The proprietary score of 28 out of 100 categorizes the company as "RISKY," and the overall financial health appears weak, with a negative five-year sales growth rate of 22.95%.<BR><BR>Given these factors, the results can be characterized as bad, and investors may need to reassess their positions in light of the company's deteriorating fundamentals and operational instability.

How has been the historical performance of Vaxtex Cotfab?

Vaxtex Cotfab has experienced significant financial fluctuations, with net sales declining from 75.62 Cr in Mar'23 to 5.25 Cr in Mar'25, leading to negative operating profits. However, there are signs of recovery, as profit after tax improved to 0.88 Cr in Mar'25 from a loss of -8.83 Cr in Mar'24, and cash flow from operations turned positive at 1.00 Cr in Mar'25.

Answer:<BR>The historical performance of Vaxtex Cotfab shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vaxtex Cotfab's net sales have seen a dramatic decline from 75.62 Cr in Mar'23 to just 5.25 Cr in Mar'25, indicating a downward trend in revenue generation. The total operating income followed a similar pattern, dropping from 75.62 Cr in Mar'23 to 5.25 Cr in Mar'25. This decline in sales has led to negative operating profits, with an operating profit of -0.51 Cr in Mar'25 compared to a positive 3.01 Cr in Mar'22. The profit before tax also reflects this trend, moving from 2.01 Cr in Mar'22 to 0.41 Cr in Mar'25. Despite these challenges, the profit after tax showed a recovery to 0.88 Cr in Mar'25 from a loss of -8.83 Cr in Mar'24. The company's total liabilities decreased from 69.48 Cr in Mar'23 to 48.29 Cr in Mar'25, while total assets also fell from 69.48 Cr to 48.29 Cr in the same period. Cash flow from operating activities remained negative in previous years but turned positive at 1.00 Cr in Mar'25, suggesting improved operational efficiency. Overall, Vaxtex Cotfab's financial performance has been volatile, with significant losses in recent years, but there are signs of recovery in the latest fiscal year.

How has been the historical performance of Vaxtex Cotfab?

Vaxtex Cotfab has faced significant revenue declines, with net sales dropping from 75.62 Cr in Mar'23 to 5.25 Cr in Mar'25, while operating profit remained negative. However, there are signs of recovery in profitability and positive cash flow in the most recent year.

Answer:<BR>The historical performance of Vaxtex Cotfab shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vaxtex Cotfab's net sales have experienced a notable decline, dropping from 75.62 Cr in Mar'23 to just 5.25 Cr in Mar'25. This decline is mirrored in total operating income, which also fell sharply from 75.62 Cr in Mar'23 to 5.25 Cr in Mar'25. The company's total expenditure, excluding depreciation, decreased from 76.00 Cr in Mar'23 to 5.76 Cr in Mar'25, indicating a substantial reduction in operational costs. However, the operating profit (PBDIT) has remained negative, with a loss of 0.51 Cr in Mar'25 compared to a loss of 0.38 Cr in Mar'23. Profit before tax showed a slight recovery, moving from a loss of 8.83 Cr in Mar'24 to a profit of 0.41 Cr in Mar'25, while profit after tax also improved to 0.88 Cr in Mar'25 from a loss of 8.83 Cr in the previous year. The company’s total assets decreased from 69.48 Cr in Mar'23 to 48.29 Cr in Mar'25, and total liabilities also fell from 69.48 Cr to 48.29 Cr during the same period. Cash flow from operating activities was positive at 1.00 Cr in Mar'25, contrasting with a negative cash flow of -47.00 Cr in Mar'24. Overall, Vaxtex Cotfab's financial performance reflects a challenging environment with significant revenue declines but some signs of recovery in profitability and cash flow in the most recent year.

Who are the top shareholders of the Vaxtex Cotfab?

The top shareholders of Vaxtex Cotfab are Qmin Industries Limited with 11.22%, Vaxfab Enterprises Limited at 6.49%, and individual investors holding 71.29%. There are no mutual funds or foreign institutional investors involved.

The top shareholders of Vaxtex Cotfab include Qmin Industries Limited, which holds the highest promoter stake at 11.22%. The highest public shareholder is Vaxfab Enterprises Limited, with a holding of 6.49%. Additionally, individual investors collectively hold a significant portion of 71.29%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Is Vaxtex Cotfab overvalued or undervalued?

As of May 9, 2023, Vaxtex Cotfab is considered overvalued and risky, with a PE ratio of 17.82, a price to book value of 0.95, and a concerning EV to EBITDA ratio of -28.55, alongside a recent stock decline of -6.06% compared to the Sensex's gain of 1.65%.

As of 9 May 2023, the valuation grade for Vaxtex Cotfab has moved from very expensive to risky, indicating a shift in perception regarding its market standing. The company is currently assessed as overvalued. Key ratios include a PE ratio of 17.82, a price to book value of 0.95, and a PEG ratio of 0.16, which suggests that despite a relatively low price to book value, the overall valuation metrics reflect significant risk.<BR><BR>In comparison to its peers, Vaxtex Cotfab's PE ratio is similar to that of other companies in the sector, but its EV to EBITDA ratio of -28.55 highlights a concerning trend compared to industry standards. Notably, the company has underperformed in recent weeks, with a stock return of -6.06% over the past week, contrasting sharply with the Sensex's gain of 1.65%. This performance, coupled with a ROCE of -33.65%, reinforces the view that Vaxtex Cotfab is currently overvalued in the market.

What is the technical trend for Vaxtex Cotfab?

As of June 6, 2025, Vaxtex Cotfab's trend is mildly bearish due to daily moving averages, despite some mixed bullish signals from weekly indicators, suggesting a cautious outlook.

As of 6 June 2025, the technical trend for Vaxtex Cotfab has changed from sideways to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend. While the weekly MACD and Bollinger Bands show mildly bullish signals, the monthly indicators are bearish, suggesting a lack of strength in the upward momentum. The KST and OBV on a weekly basis are mildly bullish, but they do not outweigh the bearish signals from the moving averages. Overall, the mixed signals across different time frames indicate a cautious outlook.

When is the next results date for Vaxtex Cotfab?

No Upcoming Board Meetings

What is the bonus history of the Vaxtex Cotfab?

Vaxtex Cotfab announced a 2:3 bonus issue with an ex-date of December 27, 2021, and a record date of December 28, 2021, allowing eligible shareholders to receive bonus shares based on this ratio.

Vaxtex Cotfab has a bonus history that includes a 2:3 bonus issue announced with an ex-date of December 27, 2021. The record date for this bonus was December 28, 2021. This means that shareholders on record as of the record date were eligible to receive the bonus shares based on the specified ratio. If you have any further questions about the company or its financials, feel free to ask!

Has Vaxtex Cotfab declared dividend?

No Dividend History Available